MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. RDNT
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

RadNet (RDNT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

RadNet
NasdaqGM•Healthcare•Diagnostics & Research
$75.78-1.34(-0.02%)Pre-market
Market Cap
$6.05B
P/S
2.7x
P/B
5.5x

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

C

How this company scores

AverageMetricSide Score: 46/100

Strongest: Growth (16/25); weakest: Cash & Earnings Quality (7/25).

Profitability11/25
Growth16/25
Balance Sheet & Red Flags12/25
Cash & Earnings Quality7/25
Strengths
Growing revenueLong cash runwayConsistent growthImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 1930.7x5y range 42.3x – 1930.7x
P/E 1930.7x · above its 11-quarter median

Currently above its 11-quarter median.

P/S · 2.7x5y range 0.7x – 2.9x
P/S 2.7x · above its 20-quarter median

Currently above its 20-quarter median.

P/B · 5.5x5y range 3.1x – 7.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Watch

Operating margins declined 7.9% — watch for continued compression, which may signal competitive or cost pressure.

Earnings Quality

Red Flag

FCF consistently trails net income (avg -5.3x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume
Market Cap $6.05B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$2.27B
7Q
Q. Revenue
$622.72M
5Q
TTM EBITDA
$225.90M
3Q
TTM Op. Income
$70.78M
3Q
Q. Op. Income
$39.47M
28%
TTM Net Income
$-21.12M
42%
Q. Net Income
$7.53M
48%
EPS
$0.1
47%
Shares Out.
$77.79M
4Q
$2.27B in TTM revenue grew 18.9% YoY, reaching $622.72M last quarter. TTM EBITDA of $225.90M and TTM operating income of $70.78M show growth is flowing through to the bottom line. However, net income is negative at $21.12M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
13.6%
2%
Op. Margin
6.3%
2%
Net Margin
1.2%
58%
Op. margin of 6.3% is up 0.1% YoY — cost efficiency is improving. Net margin at 1.2% Over the past year, operating margin is up 2% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
2.7x
20%
P/B Ratio
5.5x
22%
P/S of 2.7x and P/B of 5.5x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$4.23B
7Q
Cash
$726.27M
13%
Long-Term Debt
$1.30B
21%
Book Value
$1.10B
18%
D/E Ratio
1.2
2Q
Debt/EBITDA
15.3
5%
With $4.23B in assets and $1.30B in long-term debt, D/E is 1.2and book value is $1.10B — moderate leverage. Across the last 8 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$94.10M
22%
TTM Free Cash Flow
$72.37M
5%
FCF Margin
3.2%
20%
FCF / Net Income
-3.4
33%
TTM FCF of $72.37M on $94.10M in operating cash flow. The FCF / Net Income ratio of -3.4x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is down 5% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 5.5x
· above its 20-quarter median

Currently above its 20-quarter median.

Cash Burn

Watch

FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.

Share Dilution

Red Flag

Shares outstanding increased 5.8% — significant dilution, likely from stock compensation or capital raises.